Our Unique Approach—Targeted analysis of cancer-Related Genes

Foundation Medicine provides analysis of tumors to help better identify cancer subtypes – and help oncologists develop personalized treatment strategies for cancer patients.

Foundation Medicine's first molecular test for solid tumors, FoundationOne^tm provides precise genomic information about your cancer in a way never before available.

Please visit www.FoundationOne.com for complete information about FoundationOne.

Advanced molecular testing method

Foundation Medicine uses a sophisticated laboratory method called next-generation sequencing to perform molecular analysis on tumor biopsy samples.

All of the most relevant cancer-related genes are examined in a clinically-relevant time frame and with great precision. Our test is optimized to identify the somatic alterations in your cancer tissue.

Any type of malignant solid tumor, relevant genomic alterations

FoundationOne is unlike other available tests. It looks for genomic alterations present in any type of solid tumor, using a very small amount of biopsy tissue, to perform extensive analysis of relevant cancer-related genes.

Many available molecular tests are designed for testing only certain types of cancer. They detect only a few specific alterations that occur at high frequency in those tumor types.

FoundationOne gives your doctor the opportunity to find many more relevant genomic alterations in your cancer than is provided by other available methods.

Comprehensive analysis and results

Your results are presented to your oncologist along with interpretive information drawn from a knowledge base of publicly available scientific and medical literature, clinical trials, and genomic research. This helps your oncologist make individualized treatment recommendations specific to you and optimize your overall cancer treatment plan.

Commercial Availability

Please visit www.FoundationOne.com to learn more about molecular testing with FoundationOne.